Please Wait

Applying Filters...

Loprox Cream
CEP/COS
Table View

CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

Data Compilation
#PharmaFlow

Pipeline Prospector September 2025: Genmab buys Merus for ~US$ 8 billion, Pfizer buys Metsera to enter obesity race

Stock Recap
#PipelineProspector

Loprox cream

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

12 API Suppliers, 6 USDMF, 5 CEP/COS, 1 KDMF, 5 NDC API, 6 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers, 32 FDA Orange Book, 53 Europe, 5 Canada, 1 South Africa, 3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CREAM;TOPICAL - 0.77%, SUSPENSION;TOPICAL - 0.77%, GEL;TOPICAL - 0.77% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;TOPICAL - 8% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SHAMPOO;TOPICAL - 1%

RELATED EXCIPIENT COMPANIES

1 Seqens, 1 DKSH, 5 Nanjing Well Pharmaceutical, 1 Kirsch Pharma, 2 Actylis, 8 BASF, 2 Corel Pharma Chem, 1 Finar, 2 Lubrizol Life Science Health, 1 Pluviaendo, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

13 Topical, 7 Parenteral, 5 Solubilizers, 3 Thickeners and Stabilizers, 3 Film Formers & Plasticizers, 3 Granulation, 2 Emulsifying Agents, 2 Lubricants & Glidants, 2 Taste Masking, 2 Coating Systems & Additives, 1 Controlled & Modified Release, 1 Direct Compression, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

6 News #PharmaBuzz

6 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 US Medicaid Prescriptions, 38 Regulatory FDF Prices

MARKET PLACE

9 APIs

9 APIs

REF. STANDARDS & IMPURITIES

4 EDQM, 10 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
27/09/2025	Seqens	France	PCAS Ecully FR	R1-CEP 2004-010 - Rev 02	Ciclopirox	2020-07-31	Valid	Chemical		1407
27/09/2025	Erregierre SpA	Italy	Erregierre S.p.A. San Paolo D'Argon IT	R1-CEP 2002-210 - Rev 03	Ciclopirox	2019-03-07	Valid	Chemical		1407

Contact us
to update this info

Loprox Cream

Loprox cream

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

12 API Suppliers

6 USDMF

5 CEP/COS

1 KDMF

5 NDC API

6 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers

32 FDA Orange Book

53 Europe

5 Canada

1 South Africa

3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CREAM;TOPICAL - 0.77%

SUSPENSION;TOPICAL - 0.77%

GEL;TOPICAL - 0.77% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;TOPICAL - 8% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SHAMPOO;TOPICAL - 1%

RELATED EXCIPIENT COMPANIES

1 Seqens

1 DKSH

5 Nanjing Well Pharmaceutical

1 Kirsch Pharma

2 Actylis

8 BASF

2 Corel Pharma Chem

1 Finar

2 Lubrizol Life Science Health

1 Pluviaendo

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

13 Topical

7 Parenteral

5 Solubilizers

3 Thickeners and Stabilizers

3 Film Formers & Plasticizers

3 Granulation

2 Emulsifying Agents

2 Lubricants & Glidants

2 Taste Masking

2 Coating Systems & Additives

1 Controlled & Modified Release

1 Direct Compression

1 Surfactant & Foaming Agents

DIGITAL CONTENT

6 News #PharmaBuzz

GLOBAL SALES INFORMATION

11 US Medicaid Prescriptions

38 Regulatory FDF Prices

MARKET PLACE

9 APIs

REF. STANDARDS & IMPURITIES

4 EDQM

10 Others

Filters

GEL;TOPICAL - 0.77% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;TOPICAL - 8% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons